<DOC>
	<DOCNO>NCT01106417</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary efficacy NeoFuse subject diagnosis degenerative disc disease ( DDD ) 2 adjacent cervical vertebral level C3-C4 C7-T1 . All subject study undergo 2 3 level anterior cervical discectomy fusion Anterior Cervical Plate Fixation .</brief_summary>
	<brief_title>Safety Efficacy Study NeoFuse Subjects Undergoing Multi-Level Anterior Cervical Discectomy Fusion</brief_title>
	<detailed_description>This prospective , multicenter , randomize , single-blinded , control study evaluate safety preliminary efficacy immunoselected , culture-expanded , nucleated , allogeneic MPCs ( NeoFuse ) combine MasterGraft Matrix commercially available PEEK cervical Spacer compare active control subject undergo 2 3 level anterior cervical discectomy fusion anterior cervical plate fixation . After screen surgical visit , subject evaluate clinically radiographically within 3 day 30 day surgery , 3 , 6 , 12 , 24 month surgery . Subjects evaluate time point safety .</detailed_description>
	<mesh_term>Spondylolisthesis</mesh_term>
	<mesh_term>Spinal Stenosis</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>1 . Male female 18 70 year age , inclusive . 2 . Has ability understand requirement study , provide write informed consent , comply study protocol . 3 . Has ability understand provide write authorization use disclosure personal health information ( PHI ) . 4 . Has document symptomatic diagnosis DDD C3C4 C7T1 . 5 . Has symptomatic radiculopathy and/or myelopathy correlate radiographic finding duration 6 week great fail respond nonoperative management 6 . Is candidate anterior cervical discectomy fusion two three adjacent cervical interbody level C3C4 C7T1 7 . Has stable screen electrocardiogram ( ECG ) , determine investigator would preclude surgery . 1 . Female subject pregnant nursing , woman plan become pregnant first year ( 12 month ) follow surgery . 2 . Has current prior history within last 3 year neoplasm ( exclude basal cell carcinoma ) and/or active neoplasm within last 24 month , prior screen . 3 . Has time surgery systemic local infection site propose surgery . 4 . Has undergoing revision prior fusion surgery involve level . 5 . Requires ACDF one cervical interbody level 3 adjacent cervical interbody level . 6 . Requires ACDF without use anterior cervical plating system . 7 . Has osteoporosis define DEXA T score â‰¤ 3.0 history fragility fracture significant bone disease contraindicate use spinal instrumentation . 8 . Has document medical history radiographic evidence metabolic bone disease condition would negatively impact bone heal process . 9 . Has positive screen human immunodeficiency virus ( HIV ) antibody . 10 . Has treatment investigational therapy device within 6 month study surgery and/or plan participate allogeneic stem cell/progenitor cell therapy trial 2year followup period . 11 . Has recipient prior stem cell/progenitor cell therapy spinal fusion surgery . 12 . Has 20 % great antihuman leukocyte antigen ( HLA ) antibody titer and/or antibody specificity donor HLA antigen . 13 . Is transient treat last 6 month enrollment alcohol and/or drug abuse inpatient substance abuse program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cervical Degenerative Disc Disease</keyword>
	<keyword>Degenerative Spondylolisthesis</keyword>
	<keyword>Spinal Stenosis</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Adult Stem Cells</keyword>
	<keyword>Anterior cervical discectomy Fusion ( ACDF )</keyword>
	<keyword>Anterior Cervical Plate Fixation</keyword>
</DOC>